Abstract
Immune dysregulation and tendency for inflammation are risk factors for severe COVID-19 as described in several autoimmune disorders. Similarly, the clinical course of patients with immune dysregulation secondary to inborn errors of immunity in COVID could also be severe as shown in NFKB1 and NFKB2 deficient patients. However, data is limited on clinical and laboratory features of patients with COVID-19 and/or SARS-CoV-2 immunization and cytotoxic T-lymphocyte associated protein 4 (CTLA-4) deficiency, which is the focus of our study.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
